Aurinia Pharmaceuticals (AUPH) - Cash Funds Calculated per Share

Risks of single-product dependence on one drug determine the cash per share trend, which this GURU.Markets chart captures at 3.66. Patent protection for lupus therapy ensures sales stability, while future growth is based on R&D developments of new immunosuppressive molecules for kidney treatment. The high scientific potential of Aurinia Pharmaceuticals (AUPH) supports current asset liquidity.
Analytical breakdowns for Aurinia Pharmaceuticals Inc. (AUPH)

This indicator determines the real value of liquid assets per share, allowing for an assessment of the company's intrinsic value regardless of market volatility. By analyzing the cash per share on a quarterly basis for Aurinia Pharmaceuticals (AUPH), an investor can see the business's ability to fund the development of Lupkynis using its own resources, which minimizes the risks of equity dilution.